LB PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- –
- Dividend yield
- –
About Lb Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
LB Pharmaceuticals Inc. is a late-stage biopharmaceutical company focused on developing therapies for various neuropsychiatric disorders, including schizophrenia, bipolar depression, and major depressive disorder. The company’s core effort centers on its lead product candidate, LB-102, a methylated derivative of amisulpride designed as a benzamide antipsychotic drug. LB-102 addresses positive, negative, and cognitive symptoms across clinical evaluations, aiming to serve patients who suffer from persistent psychiatric and mood conditions.
The company maintains its principal executive offices in New York, New York, within the United States. Its clinical pipeline and regulatory activities target patients domestically and internationally, with ongoing late-stage clinical evaluations initiated in the United States. LB Pharmaceuticals conducts research and clinical trials, utilizing third-party manufacturers, service providers, and contract research organizations to support the development and operational scale of its pharmaceutical candidates.
Summary of the business section of Lb Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- LB PHARMACEUTICALS INC
- Headquarters
- New York, NY
- Address
- 575 Madison Avenue 10022
- Phone
- (917) 450-6581
- Website
- lbpharma.us
- Employees
- 27, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C, New York
Stock & identifiers
- Ticker
- LBRX
- Exchange
- Nasdaq
- IPO date
- Sep 12, 2025
- Shares outstanding
- 32M, Aug 5, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1691082
- CUSIP
- 50180M108
- ISIN
- US50180M1080
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Heather D. Turner | Chief Executive Officer, Director | – |
| Susan Gani Kozauer | Chief Medical Officer | – |
| Joseph M. Miller | Chief Financial Officer | – |
| Panandiker Kaya Kamlesh Pai | Chief Commercial Officer | – |
| Marc L. Panoff | Senior Vice President, Finance | 10,242 |
| Gad Soffer | Chief Business Officer | – |
| Anna Eramo | Chief Medical Officer | 3,585 |
| Richard Anthony Silva | SVP, Technical Operations | – |
| Robert R. Ruffolo | Director | 2,365 |
| Rekha Hemrajani | Director | – |
| William P. Kane Jr | Director | – |
| Ran Nussbaum | Director | 1,411,681 |
| Rebecca Luse | Director | – |
| Robert A. Lenz | Director | – |
| J. Scott Garland | Director | – |
| Zachary Prensky | Director | 61,274 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 12, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 9, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |